IPP Bureau

Quest Diagnostics completes acquisition of Spectra Laboratories’ Clinical Testing Assets from Fresenius Medical Care
Quest Diagnostics completes acquisition of Spectra Laboratories’ Clinical Testing Assets from Fresenius Medical Care

By IPP Bureau - August 08, 2025

Quest will now offer dialysis-related clinical testing services to independent dialysis clinics

Primelaze introduces Q-Switched Nd:YAG laser technology in India for skin treatments
Primelaze introduces Q-Switched Nd:YAG laser technology in India for skin treatments

By IPP Bureau - August 08, 2025

The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation

IOL Chemicals post Q1 FY26 consolidated profit at Rs. 33.93 Cr
IOL Chemicals post Q1 FY26 consolidated profit at Rs. 33.93 Cr

By IPP Bureau - August 08, 2025

IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025

Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr
Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr

By IPP Bureau - August 08, 2025

Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025

ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia
ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia

By IPP Bureau - August 08, 2025

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men

WACKER and Gearbox Biosciences collaborate to advance pDNA manufacturing technologies
WACKER and Gearbox Biosciences collaborate to advance pDNA manufacturing technologies

By IPP Bureau - August 08, 2025

The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

By IPP Bureau - August 08, 2025

Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore

Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg
Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg

By IPP Bureau - August 07, 2025

This is the group’s first NoC approval in Canada

Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr
Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr

By IPP Bureau - August 06, 2025

The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore

Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%

By IPP Bureau - August 06, 2025

The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter

Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

By IPP Bureau - August 06, 2025

Cenexi reports an EBITDA breakeven for the quarter

AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients
AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients

By IPP Bureau - August 06, 2025

The submission is supported by positive results from the Phase 3 AMPLIFY trial

Athena Diagnostics enhances Ataxia testing with long-read gene sequencing
Athena Diagnostics enhances Ataxia testing with long-read gene sequencing

By IPP Bureau - August 06, 2025

Athena is also exploring the use of this technology for expanded carrier screening

AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata
AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata

By IPP Bureau - August 06, 2025

The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage

Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines

By IPP Bureau - August 06, 2025

Vasograin Plus represents a major advancement in the treatment of migraine

Latest Stories

Interviews

Packaging